# Title

 Food and Drugs. PART 890â€”PHYSICAL MEDICINE DEVICES


# ID

 CFR-2018-title21-vol8.Pt. 890


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'greater than', 'after', 'greater', 'prior to']                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Condition   | ['if', 'where', 'subject to', 'when', 'unless']                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Entities    | ['Power', 'Miniature', 'Electric', 'Diagnostic', 'Moist', 'Daily', 'Isokinetic', 'Plinth', 'Shortwave', 'Ultrasonic', 'Crutch', 'Paraffin', 'Ultrasound', 'American', 'Traction', 'Exercise', 'Arm', 'Wheelchair', 'Flotation', 'Mechanical', 'Electrode', 'Scope', 'Truncal', 'External', 'Food', 'Cane', 'Microwave', 'Cold', 'Portable', 'Infrared', 'Performance', 'Iontophoresis', 'Standup', 'Immersion', 'Vitro Cytotoxicity', 'Manual', 'Powered', 'Limb', 'Physician', 'Guidance', 'Upper'] |
| Date        | ['2018-01-02', '1996-12-26', '1999-07-13', '1976-05-28']                                                                                                                                                                                                                                                                                                                                                                                                                                             |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                  |
|:--------------|:-----------------------------------------------------------------------------------------------------------------------------------------|
| after         | III (premarket approval) shall not be commercially distributed after the date shown in the regulation classifying the                    |
| before        | Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a                             |
| before        | Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a                             |
| after         | the grace period ending on the 90th day after its promulgation or on the last day of                                                     |
| after         | the grace period ending on the 90th day after its promulgation or on the last day of                                                     |
| after         | equivalent, device introduced into commercial distribution on or after May 28, 1976, includiing a device formerly marketed               |
| before        | or declaring completed a PDP for the device before the device is commercially distributed unless it is                                   |
| before        | an approval under section 515 of the act before  commercial distribution.                                                                |
| within        | or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of                |
| before        | must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce             |
| within        | by the patient in the intended use environment. within                                                                                   |
| greater than  | including a simultaneously powered elbow and/or shoulder with greater than two simultaneous powered degrees of freedom and controlled    |
| greater than  | including a simultaneously powered elbow and/or shoulder with greater than two simultaneous powered degrees of freedom and controlled    |
| greater than  | controlled electrical components such as switches) to provide greater than two independent and simultaneously powered degrees of freedom |
| after         | and available safeguard(s) under worst case conditions and after  durability testing.                                                    |
| greater       | against activities that may put the user at greater  risk (e.g., driving).                                                               |
| after         | commands and safeguard under worst case conditions and after durability testing; (iii) Verification and validation of manual             |
| greater       | and environments that may put the user at greater  risk.                                                                                 |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any rigid pneumatic structure                                   |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any rigid pneumatic structure                                   |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any rigid pneumatic structure                                   |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any rigid pneumatic structure                                   |
| before        | PMA or a declared completed PDP in effect before  being placed in commercial distribution.                                               |
| within        | and that is intended to generate deep heat within body tissues for the treatment of selected medical                                     |
| within        | means other than the generation of deep heat within body tissues as described in paragraph (a) of                                        |
| before        | with the Food and Drug Administration on or before July 13, 1999, for any microwave diathermy described                                  |
| before        | with the Food and Drug Administration on or before July 13, 1999, for any microwave diathermy described                                  |
| before        | with the Food and Drug Administration on or before July 13, 1999, for any microwave diathermy described                                  |
| before        | with the Food and Drug Administration on or before July 13, 1999, for any microwave diathermy described                                  |
| before        | approved PMA or declared completed PDP in effect before  being placed in commercial distribution.                                        |
| within        | and that is intended to generate deep heat within body tissues for the treatment of selected medical                                     |
| within        | means other than the generation of deep heat within body tissues as described in paragraph (a) of                                        |
| prior to      | (vi) Nonthermal shortwave therapy devices marketed  prior to the effective date of this reclassification must submit                     |
| within        | and that is intended to generate deep heat within body tissues for the treatment of selected medical                                     |
| within        | means other than the generation of deep heat within body tissues as described in paragraph (a) of                                        |
| before        | with the Food and Drug Administration on or before July 13, 1999, for any ultrasonic diathermy described                                 |
| before        | with the Food and Drug Administration on or before July 13, 1999, for any ultrasonic diathermy described                                 |
| before        | with the Food and Drug Administration on or before July 13, 1999, for any ultrasonic diathermy described                                 |
| before        | with the Food and Drug Administration on or before July 13, 1999, for any ultrasonic diathermy described                                 |
| before        | approved PMA or declared completed PDP in effect before  being placed in commercial distribution.                                        |
| within        | and that is intended to generate deep heat within body tissues for the treatment of selected medical                                     |
| within        | means other than the generation of deep heat within body tissues and the stimulation or relaxation of                                    |
| before        | with the Food and Drug Administration on or before July 13, 1999 for any ultrasound and muscle                                           |
| before        | with the Food and Drug Administration on or before July 13, 1999 for any ultrasound and muscle                                           |
| before        | with the Food and Drug Administration on or before July 13, 1999 for any ultrasound and muscle                                           |
| before        | with the Food and Drug Administration on or before July 13, 1999 for any ultrasound and muscle                                           |
| before        | approved PMA or declared completed PDP in effect before  being placed in commercial distribution.                                        |


## Condition

| Condition   | Context                                                                                                              |
|:------------|:---------------------------------------------------------------------------------------------------------------------|
| subject to  | of every device that is, or will be, subject to  the regulation.                                                     |
| unless      | Regulations are to chapter I of title 21, unless  otherwise noted.                                                   |
| unless      | date shown in the regulation classifying the device unless the manufacturer has an approval under section 515        |
| unless      | Accordingly,  unless an effective date of the requirement for premarket                                              |
| unless      | the device before the device is commercially distributed unless  it is reclassified.                                 |
| where       | or the device is intended for lay use where the former intended use was by health care                               |
| when        | other than immunoglobulin G (IgG) or IgG assays when the results are not qualitative, or are used                    |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to &#167;&#8201;890.9 and the following conditions for exemption: (1) |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| when        | is a device intended for medical purposes that, when put together with other appropriate components, constitutes a   |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| if          | safety, battery performance and safety, and wireless performance, if  applicable.                                    |
| if          | (iii) Ver if ication and validation of force sensors and hand                                                        |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| if          | safety, battery performance and safety, and wireless performance, if  applicable.                                    |
| if          | case conditions and after durability testing; (iii) Ver if ication and validation of manual override controls are    |
| when        | capture any adverse events observed during clinical use when used under the proposed conditions of use, which        |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| when        | is used to assist a patient in communicating when physical impairment prevents writing, telephone use, reading, or   |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to &#167;&#8201;890.9 and the following conditions for exemption: (i) |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to &#167;&#8201;890.9 and the following conditions for exemption: (i) |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| if          | diagnosis of cystic fibrosis or for other uses if the labeling of the drug intended for use                          |
| if          | drug approved for iontophoretic delivery, or a solution, if  ident                                                   |
| if          | drug approved for iontophoretic delivery, or a solution, if  ident                                                   |
| when        | appropriate warnings and contraindications, including the following warning: when                                    |
| if          | drug labeling approved for iontophoretic delivery to determine if  the drug they intend to deliver is spec           |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| when        | Except  when intended for use on infants, the device is                                                              |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | in subpart E part 807 of this chapter subject to  &#167;&#8201;890.9.                                                |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9                             |
|             |               Powered heating unit.                                                                                  |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |
| subject to  | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;890.9.                            |


## Entities

| Entities           | Context                                                                                                                                                  |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food               | Food  and Drugs.                                                                                                                                         |
| Scope              | Scope .                                                                                                                                                  |
| Electrode          | Electrode  cable.                                                                                                                                        |
| Guidance           | chapter, and (2) The guidance document entitled &#8220; Guidance on the Performance Standard for Electrode Lead Wires                                    |
| Diagnostic         | Diagnostic  electromyograph.                                                                                                                             |
| Diagnostic         | Diagnostic  electromyograph needle electrode.                                                                                                            |
| Powered            | Powered  reflex hammer.                                                                                                                                  |
| Miniature          | Miniature  pressure transducer.                                                                                                                          |
| Diagnostic         | Diagnostic  muscle stimulator.                                                                                                                           |
| Isokinetic         | Isokinetic  testing and evaluation system.                                                                                                               |
| Cane               | Cane .                                                                                                                                                   |
| Mechanical         | Mechanical  chair.                                                                                                                                       |
| Electric           | Electric  positioning chair.                                                                                                                             |
| Vitro Cytotoxicity | Evaluation of Medical Devices&#8212;Part 5: Tests for In Vitro Cytotoxicity ,&#8221; and ANSI/AAMI/ISO 10993-10, &#8220;Biological Evaluation of Medical |
| Crutch             | Crutch .                                                                                                                                                 |
| Flotation          | Flotation  cushion.                                                                                                                                      |
| Upper              | Upper extremity prosthesis including a simultaneously powered elbow and/or                                                                               |
| Performance        | Performance testing must include: (i) Mechanical bench data, including                                                                                   |
| Limb               | Limb  orthosis.                                                                                                                                          |
| Powered            | Powered  lower extremity exoskeleton.                                                                                                                    |
| Performance        | Performance testing must include: (i) Mechanical bench testing (including                                                                                |
| Physician          | (8) Labeling for the  Physician and User must include the following: (i) Appropriate                                                                     |
| Truncal            | Truncal  orthosis.                                                                                                                                       |
| External           | External  assembled lower limb prosthesis.                                                                                                               |
| Plinth             | Plinth .                                                                                                                                                 |
| Arm                | Arm  sling.                                                                                                                                              |
| Powered            | Powered  environmental control system.                                                                                                                   |
| Mechanical         | Mechanical  table.                                                                                                                                       |
| Powered            | Powered  table.                                                                                                                                          |
| Cane               | Cane , crutch, and walker tips and pads.                                                                                                                 |
| Cane               | Cane , crutch, and walker tips and pads are                                                                                                              |
| Mechanical         | Mechanical  walker.                                                                                                                                      |
| Mechanical         | Mechanical  wheelchair.                                                                                                                                  |
| Powered            | Powered  wheelchair.                                                                                                                                     |
| Performance        | Performance testing must include the following: (i) Fatigue testing;                                                                                     |
| Standup            | Standup  wheelchair.                                                                                                                                     |
| Wheelchair         | Wheelchair  accessory.                                                                                                                                   |
| Wheelchair         | Wheelchair  component.                                                                                                                                   |
| Wheelchair         | Wheelchair  elevator.                                                                                                                                    |
| Portable           | (b)  Portable  wheelchair elevators&#8212;(1) Identification.                                                                                            |
| Wheelchair         | Wheelchair  platform scale.                                                                                                                              |
| Daily              | Daily  activity assist device.                                                                                                                           |
| Immersion          | Immersion  hydrobath.                                                                                                                                    |
| Paraffin           | Paraffin  bath.                                                                                                                                          |
| Powered            | Powered  patient transport.                                                                                                                              |
| American           | that outlined in the currently FDA-recognized edition of American Society of Mechanical Engineers (ASME) A18.1 &#8220;Safety Standard                    |
| Manual             | Manual  patient rotation bed.                                                                                                                            |
| Powered            | Powered  patient rotation bed.                                                                                                                           |
| Moist              | Moist  steam cabinet.                                                                                                                                    |
| Microwave          | Microwave  diathermy.                                                                                                                                    |
| Shortwave          | Shortwave  diathermy.                                                                                                                                    |
| Ultrasonic         | Ultrasonic  diathermy.                                                                                                                                   |
| Exercise           | Exercise  component.                                                                                                                                     |
| Powered            | Powered  finger exerciser.                                                                                                                               |
| Infrared           | Infrared  lamp.                                                                                                                                          |
| Iontophoresis      | Iontophoresis  device.                                                                                                                                   |
| Powered            | Powered  external limb overload warning device.                                                                                                          |
| Powered            | Powered  inflatable tube massager.                                                                                                                       |
| Cold               | Cold  pack.                                                                                                                                              |
| Moist              | Moist  heat pack.                                                                                                                                        |
| Powered            | Powered  heating pad.                                                                                                                                    |
| Powered            | Powered  muscle stimulator.                                                                                                                              |
| Ultrasound         | Ultrasound  and muscle stimulator.                                                                                                                       |
| Power              | Power  traction equipment.                                                                                                                               |
| Traction           | Traction  accessory.                                                                                                                                     |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1976-05-28 | (b) Any new, not substantially equivalent, device introduced into commercial distribution on or after May 28, 1976, includiing a device formerly marketed that has been substantially altered, is classified by statute (section 513(f) of the act) into class III without any grace period and FDA must have issued an order approving a PMA or declaring completed a PDP for the device before the device is commercially distributed unless it is reclassified.                                                                                                                                                                                     |
| 1976-05-28 | Accordingly, the regulation for such a class III device states that as of the enactment date of the amendments, May 28, 1976, the device must have an approval under section 515 of the act before commercial distribution.                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 2018-01-02 | The electric positioning chair is exempt from premarket notification procedures in subpart E of part 807 of this chapter, subject to &#167;&#8201;890.9 and the following conditions for exemption:                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (1) Appropriate analysis and non-clinical testing must demonstrate that the safety controls are adequate to ensure safe use of the device and prevent user falls from the device in the event of a device failure;                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (2) Appropriate analysis and non-clinical testing must demonstrate the ability of the device to withstand the rated user weight load with an appropriate factor of safety;                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (3) Appropriate analysis and non-clinical testing must demonstrate the longevity of the device to withstand external forces applied to the device and provide the user with an expected service life of the device;                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (4) Appropriate analysis and non-clinical testing must demonstrate proper environments of use and storage of the device to maximize the longevity of the device;                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (5) Appropriate analysis and non-clinical testing (such as that outlined in the currently FDA-recognized editions of ANSI/AAMI/ES60601-1, &#8220;Medical Electrical Equipment&#8212;Part 1: General Requirements for Basic Safety and Essential Performance,&#8221; and ANSI/AAMI/IEC 60601-1-2, &#8220;Medical Electrical Equipment&#8212;Part 1-2: General Requirements for Basic Safety and Essential Performance&#8212;Collateral Standard: Electromagnetic Disturbances&#8212;Requirements and Tests&#8221;) must validate electromagnetic compatibility and electrical safety;                                                     |
|            |               (6) Appropriate analysis and non-clinical testing (such as that outlined in the currently FDA-recognized editions of ANSI/AAMI/ISO 10993-1, &#8220;Biological Evaluation of Medical Devices&#8212;Part 1: Evaluation and Testing Within a Risk Management Process,&#8221; ANSI/AAMI/ISO 10993-5, &#8220;Biological Evaluation of Medical Devices&#8212;Part 5: Tests for In Vitro Cytotoxicity,&#8221; and ANSI/AAMI/ISO 10993-10, &#8220;Biological Evaluation of Medical Devices&#8212;Part 10: Tests for Irritation and Skin Sensitization&#8221;) must validate that the skin-contacting components of the device are biocompatible; |
|            |               (7) Appropriate analysis and non-clinical testing (such as that outlined in the currently FDA-recognized editions of IEC 62304, &#8220;Medical Device Software&#8212;Software Life Cycle Processes&#8221;) must validate the software life cycle and that all processes, activities, and tasks are implemented and documented;                                                                                                                                                                                                                                                                                                           |
|            |               (8) Appropriate analysis and non-clinical testing must validate that the device components are found to be non-flammable;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (9) Appropriate analysis and non-clinical testing must validate that the battery in the device (if applicable) performs as intended over the anticipated service life of the device; and                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (10) Adequate patient labeling is provided to the user to document proper use and maintenance of the device to ensure safe use of the device by the patient in the intended use environment.                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1996-12-26 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any rigid pneumatic structure orthosis that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a rigid pneumatic structure orthosis that was in commercial distribution before May 28, 1976.                                                                                                                                                                                                                       |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any rigid pneumatic structure orthosis that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a rigid pneumatic structure orthosis that was in commercial distribution before May 28, 1976.                                                                                                                                                                                                                       |
| 1996-12-26 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any rigid pneumatic structure orthosis that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a rigid pneumatic structure orthosis that was in commercial distribution before May 28, 1976.                                                                                                                                                                                                                       |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any rigid pneumatic structure orthosis that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a rigid pneumatic structure orthosis that was in commercial distribution before May 28, 1976.                                                                                                                                                                                                                       |
| 2018-01-02 | (iii) Appropriate analysis and nonclinical testing (such as that outlined in the currently FDA-recognized edition of ASME A18.1 &#8220;Safety Standard for Platform Lifts and Stairway Chair Lifts&#8221;) must demonstrate the ability of the enclosures to prevent the user from falling from the device; and                                                                                                                                                                                                                                                                                                                                        |
|            |               (iv) Appropriate analysis and nonclinical testing (such as that outlined in the currently FDA-recognized editions of AAMI/ANSI/IEC 60601-1-2, &#8220;Medical Electrical Equipment&#8212;Part 1-2: General Requirements for Safety&#8212;Collateral Standard: Electromagnetic Compatibility&#8212;Requirements and Tests,&#8221; and ASME A18.1 &#8220;Safety Standard for Platform Lifts and Stairway Chair Lifts&#8221;) must validate electromagnetic compatibility and electrical safety.                                                                                                                                             |
| 2018-01-02 | The stairway chair lift is exempt from premarket notification procedures in subpart E of part 807 of this chapter, subject to &#167;&#8201;890.9 and the following conditions for exemption:                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (i) Appropriate analysis and nonclinical testing (such as that outlined in the currently FDA-recognized edition of American Society of Mechanical Engineers (ASME) A18.1 &#8220;Safety Standard for Platform Lifts and Stairway Chair Lifts&#8221;) must demonstrate that the safety controls are adequate to prevent a free fall of the chair in the event of a device failure;                                                                                                                                                                                                                                                         |
|            |               (ii) Appropriate analysis and nonclinical testing must demonstrate the ability of the device, including armrests, to withstand the rated load with an appropriate factor of safety;                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (iii) Appropriate restraints must be provided to prevent the user from falling from the device (such as that outlined in the currently FDA-recognized edition of ASME A18.1 &#8220;Safety Standard for Platform Lifts and Stairway Chair Lifts&#8221;);                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (iv) Appropriate analysis and nonclinical testing (such as that outlined in the currently FDA-recognized editions of AAMI/ANSI/IEC 60601-1-2, &#8220;Medical Electrical Equipment&#8212;Part 1-2: General Requirements for Safety&#8212;Collateral Standard: Electromagnetic Compatibility&#8212;Requirements and Tests,&#8221; and ASME A18.1 &#8220;Safety Standard for Platform Lifts and Stairway Chair Lifts&#8221;) must validate electromagnetic compatibility and electrical safety; and                                                                                                                                         |
|            |               (v) Appropriate analysis and nonclinical testing must demonstrate the resistance of the device upholstery to ignition.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1999-07-13 | A PMA or a notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999, for any microwave diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to a microwave diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                                             |
| 1976-05-28 | A PMA or a notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999, for any microwave diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to a microwave diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                                             |
| 1999-07-13 | A PMA or a notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999, for any microwave diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to a microwave diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                                             |
| 1976-05-28 | A PMA or a notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999, for any microwave diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to a microwave diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                                             |
| 1999-07-13 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999, for any ultrasonic diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an ultrasonic diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                                            |
| 1976-05-28 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999, for any ultrasonic diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an ultrasonic diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                                            |
| 1999-07-13 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999, for any ultrasonic diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an ultrasonic diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                                            |
| 1976-05-28 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999, for any ultrasonic diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an ultrasonic diathermy described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                                            |
| 1999-07-13 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999 for any ultrasound and muscle stimulator described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an ultrasound and muscle stimulator described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                     |
| 1976-05-28 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999 for any ultrasound and muscle stimulator described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an ultrasound and muscle stimulator described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                     |
| 1999-07-13 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999 for any ultrasound and muscle stimulator described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an ultrasound and muscle stimulator described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                     |
| 1976-05-28 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999 for any ultrasound and muscle stimulator described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an ultrasound and muscle stimulator described in paragraph (b) of this section that was in commercial distribution before May 28, 1976.                                                                                     |


